Comunicato Stampa EMA su Pradaxa (dabigatran) (25/05/2012)

Asset Publisher

Comunicato Stampa EMA su Pradaxa (dabigatran) (25/05/2012)

L’Agenzia Europea per i Medicinali aggiorna le informazioni su Pradaxa (dabigatran) rivolte a pazienti e medici.

I dati confermano il profilo rischio-beneficio positivo del medicinale anticoagulante, ma sono necessarie modifiche alle informazioni del prodotto per fornire indicazioni più chiare

Per informazioni dettagliate leggere la documentazione in allegato:

Published on: 25 May 2012

Asset Publisher

Site Map

Safety of medicinal products

Share

Nested Applications

Highlights

30/12/2024 - AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

16/12/2024 - AIFA launches crackdown on conflict of interest. But opens the way for free opinions and consultations by high-profile professionals

ALL NEWS

News

14/01/2025

Hepatitis C: update of 13 January 2025 concerning enrolled patients

13/01/2025

Innovative medicines list: AIFA publishes December 2024 update

07/01/2025

List of class A and H medicinal products at 17 June 2024

All news

Galleria

Nested Applications

Press

AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

Aifa toggle bar Search

Aifa toggle bar Search